DBC1 is over-expressed and associated with poor prognosis in colorectal cancer

International Journal of Clinical Oncology

Volumn 19, Issue 1, 2014, Pages 106-112

  Zhang, Yongguo ^a,b   Gu, Yong ^a   Sha, Sumei ^a   Kong, Xiangyun ^a   Zhu, Hongwu ^a   Xu, Bin ^a   Li, Yijun ^a   Wu, Kaichun ^a  

^a FOURTH MILITARY MEDICAL UNIVERSITY   (China)

^b GENERAL HOSPITAL OF NORTHERN THEATER COMMAND   (China)

Author keywords

Colorectal cancer; DBC1; Prognosis; Tumor marker

Indexed keywords

AGED; COLORECTAL NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; KAPLAN-MEIER ESTIMATE; LYMPHATIC METASTASIS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; TUMOR SUPPRESSOR PROTEINS;

EID: 84894600192     PISSN: 13419625     EISSN: 14377772     Source Type: Journal    
DOI: 10.1007/s10147-012-0506-5     Document Type: Article

References (32)

1. Kamangar F, Dores GM, Anderson WF (2006) Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world. J Clin Oncol 24:2137-2150
2. Migliore L, Migheli F, Spisni R, et al. (2011) Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol 2011:792362
3. Pritchard CC, Grady WM (2011) Colorectal cancer molecular biology moves into clinical practice. Gut 60:116-129
4. Pino MS, Chung DC (2011) Microsatellite instability in the management of colorectal cancer. Expert Rev Gastroenterol Hepatol 5:385-399
5. Chu D, Li Y, Wang W, et al. (2010) High level of Notch1 protein is associated with poor overall survival in colorectal cancer. Ann Surg Oncol 17:1337-1342
6. Hamaguchi M, Meth JL, von Klitzing C, et al. (2002) DBC2, a candidate for a tumor suppressor gene involved in breast cancer. Proc Natl Acad Sci USA 99:13647-13652
7. Lee H, Kim KR, Noh SJ, et al. (2011) Expression of DBC1 and SIRT1 is associated with poor prognosis for breast carcinoma. Hum Pathol 42:204-213
8. Sung JY, Kim R, Kim JE, et al. (2010) Balance between SIRT1 and DBC1 expression is lost in breast cancer. Cancer Sci 101:1738-1744
9. Cha EJ, Noh SJ, Kwon KS, et al. (2009) Expression of DBC1 and SIRT1 is associated with poor prognosis of gastric carcinoma. Clin Cancer Res 15:4453-4459
10. Kim SH, Kim JH, Yu EJ, et al. (2012) The overexpression of DBC1 in esophageal squamous cell carcinoma correlates with poor prognosis. Histol Histopathol 27:49-58
11. Kim JE, Sung S (2010) Deleted in breast cancer 1 (DBC1) is a dynamically regulated protein. Neoplasma 57:365-368
12. Sundararajan R, Chen G, Mukherjee C, et al. (2005) Caspase-dependent processing activates the proapoptotic activity of deleted in breast cancer-1 during tumor necrosis factor-alpha-mediated death signaling. Oncogene 24:4908-4920
13. Kim JE, Chen J, Lou Z (2009) p30 DBC is a potential regulator of tumorigenesis. Cell Cycle 8:2932-2935
14. Kim JE, Chen J, Lou Z (2008) DBC1 is a negative regulator of SIRT1. Nature 451:583-586
15. Trauernicht AM, Kim SJ, Kim NH, et al. (2010) DBC-1 mediates endocrine resistant breast cancer cell survival. Cell Cycle 9:1218-1219
16. Trauernicht AM, Kim SJ, Kim NH, et al. (2007) Modulation of estrogen receptor alpha protein level and survival function by DBC-1. Mol Endocrinol 21:1526-1536
17. Suen TC, Goss PE (2001) Identification of a novel transcriptional repressor element located in the first intron of the human BRCA1 gene. Oncogene 20:440-450
18. Hiraike H, Wada-Hiraike O, Nakagawa S, et al. (2010) Identification of DBC1 as a transcriptional repressor for BRCA1. Br J Cancer 102:1061-1067
19. Garapaty S, Xu CF, Trojer P, et al. (2009) Identification and characterization of a novel nuclear protein complex involved in nuclear hormone receptor-mediated gene regulation. J Biol Chem 284:7542-7552
20. Fu J, Jiang J, Li J, et al. (2009) Deleted in breast cancer 1, a novel androgen receptor (AR) coactivator that promotes AR DNA-binding activity. J Biol Chem 284:6832-6840
21. Gomez I, Pena C, Herrera M, et al. (2011) TWIST1 is expressed in colorectal carcinomas and predicts patient survival. PLoS ONE 6:e18023
22. Chu D, Zhang Z, Li Y, et al. (2011) Prediction of colorectal cancer relapse and prognosis by tissue mRNA levels of NDRG2. Mol Cancer Ther 10:47-56
23. Ogino S, Shima K, Baba Y, et al. (2009) Colorectal cancer expression of peroxisome proliferator-activated receptor gamma (PPARG, PPARgamma) is associated with good prognosis. Gastroenterology 136:1242-1250
24. Grady WM, Carethers JM (2008) Genomic and epigenetic instability in colorectal cancer pathogenesis. Gastroenterology 135:1079-1099
25. Popat S, Hubner R, Houlston RS (2005) Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol 23:609-618
26. Nosho K, Kure S, Irahara N, et al. (2009) A prospective cohort study shows unique epigenetic, genetic, and prognostic features of synchronous colorectal cancers. Gastroenterology 137(1609-1620):e1601-e1603
27. Zhao W, Kruse JP, Tang Y, et al. (2008) Negative regulation of the deacetylase SIRT1 by DBC1. Nature 451:587-590
28. Brooks CL, Gu W (2009) How does SIRT1 affect metabolism, senescence and cancer? Nat Rev Cancer 9:123-128
29. Venkitaraman AR (2009) Linking the cellular functions of BRCA genes to cancer pathogenesis and treatment. Annu Rev Pathol 4:461-487
30. Soussi T (2000) p53 Antibodies in the sera of patients with various types of cancer: a review. Cancer Res 60:1777-1788
31. Reid JF, Gariboldi M, Sokolova V, et al. (2009) Integrative approach for prioritizing cancer genes in sporadic colon cancer. Genes Chromosomes Cancer 48:953-962
32. Macartney-Coxson DP, Hood KA, Shi HJ, et al. (2008) Metastatic susceptibility locus, an 8p hot-spot for tumour progression disrupted in colorectal liver metastases: 13 candidate genes examined at the DNA, mRNA and protein level. BMC Cancer 8:187